Tidal Investments LLC Purchases 716 Shares of Core Laboratories Inc. (NYSE:CLB)

Tidal Investments LLC increased its position in shares of Core Laboratories Inc. (NYSE:CLB) by 1.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 43,862 shares of the oil and gas company’s stock after acquiring an additional 716 shares during the period. Tidal Investments LLC owned approximately 0.09% of Core Laboratories worth $813,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Disciplined Growth Investors Inc. MN raised its holdings in shares of Core Laboratories by 446.8% in the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 4,460,720 shares of the oil and gas company’s stock valued at $90,508,000 after acquiring an additional 3,644,963 shares in the last quarter. Earnest Partners LLC raised its stake in Core Laboratories by 6.3% in the second quarter. Earnest Partners LLC now owns 3,286,438 shares of the oil and gas company’s stock valued at $66,682,000 after purchasing an additional 195,756 shares in the last quarter. Eagle Asset Management Inc. bought a new stake in Core Laboratories during the third quarter valued at approximately $3,531,000. Fisher Asset Management LLC grew its stake in Core Laboratories by 19.5% in the 3rd quarter. Fisher Asset Management LLC now owns 990,267 shares of the oil and gas company’s stock worth $18,350,000 after buying an additional 161,278 shares in the last quarter. Finally, Royce & Associates LP grew its stake in Core Laboratories by 9.0% in the 3rd quarter. Royce & Associates LP now owns 1,021,121 shares of the oil and gas company’s stock worth $18,921,000 after buying an additional 84,022 shares in the last quarter. 97.81% of the stock is currently owned by hedge funds and other institutional investors.

Core Laboratories Trading Down 4.4 %

Shares of CLB opened at $16.85 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.79 and a current ratio of 2.48. Core Laboratories Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $25.13. The firm has a 50 day moving average price of $19.62 and a 200-day moving average price of $19.67. The firm has a market cap of $791.11 million, a price-to-earnings ratio of 25.92, a PEG ratio of 1.36 and a beta of 2.35.

Core Laboratories (NYSE:CLB) last posted its quarterly earnings results on Wednesday, October 23rd. The oil and gas company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.04. Core Laboratories had a net margin of 5.83% and a return on equity of 15.84%. The business had revenue of $134.40 million during the quarter, compared to the consensus estimate of $134.16 million. During the same period in the previous year, the firm posted $0.22 earnings per share. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. As a group, equities research analysts forecast that Core Laboratories Inc. will post 0.8 earnings per share for the current year.

Core Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Monday, November 4th were given a dividend of $0.01 per share. The ex-dividend date was Monday, November 4th. This represents a $0.04 annualized dividend and a yield of 0.24%. Core Laboratories’s payout ratio is 6.15%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on CLB shares. StockNews.com raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Citigroup dropped their price target on Core Laboratories from $15.00 to $14.00 and set a “sell” rating for the company in a research note on Thursday, October 31st. Two research analysts have rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. Based on data from MarketBeat.com, Core Laboratories has a consensus rating of “Hold” and an average price target of $17.00.

Core Laboratories Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.